Unknown PHASE2 INTERVENTIONAL 1-arm NCT05675033

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Serplulimab Combined With Anti-VEGF Antibody and Platinum-based Chemotherapy in Treat-naive EGFR/ALK-negative Advanced Lung Adenocarcinoma, a Single Arm Clinical Trail

Sponsor: Fujian Cancer Hospital

Conditions Lung Adenocarcinoma PD-1 Inhibitor Stage IV Non-small Cell Lung Cancer VEGF

Interventions Serplulimab and Bevacizumab injection

Updated 4 times since 2023 Last updated: Dec 21, 2022 Started: Jan 10, 2023 Primary completion: Jan 10, 2023 Completion: Jan 10, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05675033, this PHASE2 trial focuses on Lung Adenocarcinoma and PD-1 Inhibitor and remains ongoing. Sponsored by Fujian Cancer Hospital, it has been updated 4 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Feb 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Cancer Hospital

Data source: Fujian Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.